Table 2.
Clinical outcomes of peak–trough-based versus trough-only-based vancomycin therapeutic drug monitoring approaches
| Variable | Trough-only-monitoring group | Peak–trough-monitoring group | p valuea |
|---|---|---|---|
| (n = 35) | (n = 30) | ||
| Vancomycin treatment efficacy outcomes, n (%) | |||
| Therapeutic cure | 17 (48.6) | 23 (76.7) | 0.020 |
| Therapeutic failure | 18 (51.4) | 7 (23.3) | |
| Vancomycin treatment safety outcomes, n (%) | |||
| Neutropenia | 3 (8.6) | 1 (3.3) | 0.381 |
| Nephrotoxicity | 1 (2.9) | 1 (3.3) | 0.912 |
| All-cause mortality, n (%) | 3 (8.6) | 2 (6.7) | 0.774 |
| Length of hospitalization (days), median [min–max] | 20 [6–117] | 15.5 [4–68.9] | 0.320 |
| Total duration on vancomycin treatment (days), median [min–max] | 7 [1–28] | 6.5 [1–32] | 0.319 |
aChi-squared test or Mann–Whitney U-test